Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Brain Neoplasms × tucatinib × Clear all

Phase

Status

Withdrawn 1 Unknown 1 Terminated 1 No longer available 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Stomach Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 HER2-positive Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 86 Bevacizumab 57 Radiotherapy 54 Radiosurgery 36 Carboplatin 26 Magnetic Resonance Spectroscopy 24 Irinotecan 23 Etoposide 21 Surgical Procedures, Operative 19 Carmustine 18 Filgrastim 16 Lomustine 15 Erlotinib Hydrochloride 15 Vincristine 14 Cyclophosphamide 14 Radiation 13 Lapatinib 13 Cisplatin 13 Thalidomide 11 Sorafenib 11 Imatinib Mesylate 11 Trastuzumab 10 Surveys and Questionnaires 10 Nivolumab 10 Granulocyte Colony-Stimulating Factor 10 Aminolevulinic Acid 10 Thiotepa 9 Radiotherapy, Intensity-Modulated 9 Peripheral Blood Stem Cell Transplantation 9 Everolimus 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02614794 2023-08-14

HER2CLIMB

Seagen Inc.

Phase 2 Completed

612 enrolled 30 charts 2 FDA

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡